TPX-0005 (Repotrectinib) is an orally available and potent ATP-competitive inhibitor against ALK/ROS1/pan-TRK and their corresponding constitutively active clinical resistant mutants [1] TPX-0005 inhibits cell proliferation in neuroblastoma cells and exhibits strong antitumor effects in xenograft models of neuroblastoma [2]. Clinical trial studies in patients with advanced solid tumors harboring ALK, ROS1, or NTRK1-3 rearrangements are in progress as single agent as well as in combinatory therapy [3].

TPX-0005 (Repotrectinib) is an orally available and potent ATP-competitive inhibitor against ALK/ROS1/pan-TRK and their corresponding constitutively active clinical resistant mutants [1] TPX-0005 inhibits cell proliferation in neuroblastoma cells and exhibits strong antitumor effects in xenograft models of neuroblastoma [2]. Clinical trial studies in patients with advanced solid tumors harboring ALK, ROS1, or NTRK1-3 rearrangements are in progress as single agent as well as in combinatory therapy [3].